| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Mayo Clinic/Mayo Foundation, Rochester, MN.
Address correspondence and reprint requests to Dr. John H. Noseworthy, Department of Neurology, Mayo Clinic/Mayo Foundation, 200 First Street, SW, Rochester, MN 55905; e-mail: noseworthy.john{at}mayo.edu
OBJECTIVE: To determine whether linomide (roquinimex) is better than placebo in slowing the time to confirmed clinical worsening in patients with relapsing–remitting (RR) and secondary progressive (SP) MS.
METHODS: In this 27-center, randomized, double-blind, placebo-controlled, multiple-dose, phase III trial, 715 patients with active RRMS (n = 90) or SPMS (n = 625) were randomized to receive either linomide (1.0, 2.5, or 7.5 mg orally daily) or placebo. Patients were evaluated at 3-month intervals clinically and with MRI. The planned primary outcome was the time to the development of "confirmed" clinical worsening (increase of 
1.0 Expanded Disability Status Scale [EDSS] score for an enrollment EDSS score 
5.0, or 0.5 point for an enrollment EDSS score of 5.5) not associated with an acute relapse.
RESULTS: The trial was terminated 1 month after it became fully enrolled due to unanticipated serious cardiopulmonary toxicities (pericarditis, pleural effusion, myocardial infarction, and possible pulmonary embolism), pancreatitis, and death. Notable arthralgia, myalgia, bursitis, and facial and peripheral edema were common adverse events. The high dose of linomide (7.5 mg) was not well tolerated. The trial was too brief to determine unequivocal clinical benefits. Trends suggested an unconfirmed early effect on change in EDSS score at 6 months for the medium dose (2.5 mg daily).
CONCLUSION: MS patients may be more prone to develop important linomide treatment-related adverse events than other previously studied patients. However, linomide may be a potentially more toxic drug than was suspected from observations made in smaller studies for other indications. Phase III trials may identify infrequent and important toxicities that may not be anticipated by phase I and II trials.
Key words: Linomide—MS—Randomized controlled trial—Clinical outcome measures
This article has been cited by other articles:
|
|
 |
|
  M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tuvesson, I. Hallin, R. Persson, B. Sparre, P. O. Gunnarsson, and J. Seidegard CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR Drug Metab. Dispos., June 1, 2005; 33(6): 866 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle, T. Nederman, and for the Laquinimod in Relapsing MS Study Group Treatment with laquinimod reduces development of active MRI lesions in relapsing MS Neurology, March 22, 2005; 64(6): 987 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos, B. Weinshenker, C. Pozzilli, A. J. Thompson, F. Dahlke, K. Beckmann, C. Polman, H. McFarland, and for the European and North American Interferon b Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials Neurology, November 23, 2004; 63(10): 1779 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bielekova and R. Martin Development of biomarkers in multiple sclerosis Brain, July 1, 2004; 127(7): 1463 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Siev-Ner, D Gamus, L Lerner-Geva, and A Achiron Refiexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study Multiple Sclerosis, August 1, 2003; 9(4): 356 - 361. [Abstract] [PDF]
|
|
|
|
|
|
J. Wolinsky MRI aspects of secondary progressive multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 85 - 87. [PDF]
|
|
|
|
 |
|
 J. C. Chappell and H. Cohen Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease Journal of Pharmacy Practice, June 1, 2002; 15(3): 221 - 240. [Abstract] [PDF]
|
|
|
|
|
|
J S Wolinsky MRI aspects of secondary progressive multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 85 - 87. [PDF]
|
|
|
|
 |
|
 J. N. Whitaker, J. S. Wolinsky, P. A. Narayana, A. A. Bartolucci, J. H. Noseworthy, F. D. Lublin, A. Linde, P. Gjorstrup, H. C. Sullivan, and for the North American Linomide Investigators Relationship of Urinary Myelin Basic Protein-Like Material With Cranial Magnetic Resonance Imaging in Advanced Multiple Sclerosis Arch Neurol, January 1, 2001; 58(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid, A. D. Goodman, B. R. Apatoff, P. K. Coyle, L. D. Jacobs, L. B. Krupp, A. E. Miller, K. E. Wende, C. M. Brownscheidle, and a. t. New York State Multiple Sclerosis Consortium* Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology, December 26, 2000; 55(12): 1901 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid and J. L. Trotter Lessons from linomide: A failed trial, but not a failure Neurology, May 9, 2000; 54(9): 1716 - 1717. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Wolinsky, P. A. Narayana, J. H. Noseworthy, F. D. Lublin, J. N. Whitaker, A. Linde, P. Gjorstrup, and H. C. Sullivan Linomide in relapsing and secondary progressive MS: Part II: MRI results Neurology, May 9, 2000; 54(9): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
